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Abstract
Purpose: Researchers are currently seeking relevant lung cancer biomarkers in
order to make informed decisions regarding therapeutic selection for patients in socalled ‘‘precision medicine.’’ However, there are challenges to obtaining adequate
lung cancer tissue for molecular analyses. Furthermore, current molecular testing of
tumors at the genomic or transcriptomic level are very indirect measures of
biological response to a drug, particularly for small molecule inhibitors that target
kinases. Kinase activity profiling is therefore theorized to be more reflective of
in vivo biology than many current molecular analysis techniques. As a result, this
study seeks to prove the feasibility of combining a novel minimally invasive biopsy
technique that expands the number of lesions amenable for biopsy with subsequent
ex vivo kinase activity analysis.
Methods: Eight patients with lung lesions of varying location and size were
biopsied using the novel electromagnetic navigational bronchoscopy (ENB)
technique. Basal kinase activity (kinomic) profiles and ex vivo interrogation of
samples in combination with tyrosine kinase inhibitors erlotinib, crizotinib, and
lapatinib were performed by PamStation 12 microarray analysis.
Results: Kinomic profiling qualitatively identified patient specific kinase activity
profiles as well as patient and drug specific changes in kinase activity profiles
following exposure to inhibitor. Thus, the study has verified the feasibility of ENB as
a method for obtaining tissue in adequate quantities for kinomic analysis and has
demonstrated the possible use of this tissue acquisition and analysis technique as
a method for future study of lung cancer biomarkers.
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Conclusions: We demonstrate the feasibility of using ENB-derived biopsies to
perform kinase activity assessment in lung cancer patients.

Introduction
Novel therapies for lung cancer are being tested in both preclinical and clinical
settings [1], yet little is known as to how to best select drugs for individual
patients. Recent approaches to tackle this problem have used genomic,
transcriptomic, and proteomic profiling of tissue [2–4] or blood samples [5].
However, these approaches are limited because: 1) They can be time consuming
(leading to delay in treatment); 2) Protein and gene expression often show poor
concordance (i.e., gene expression does not necessarily predict protein level) [6];
and 3) Genomic and proteomic data are very indirect measures for drug function
[7]. This is especially evident with kinase-directed therapies [8, 9] such as tyrosine
kinase inhibitors (TKI’s). Unfortunately, almost all clinical studies using TKI’s do
not attempt to measure kinase activity, even indirectly [1, 10]. Even innovative
trials like the Biomarker-integrated Approaches of Targeted Therapy for Lung
Cancer Elimination (BATTLE) Trial [11], do not include kinase activity in their
molecular characterization, despite a preponderance of TKI’s being tested. For this
reason, current biomarker utilization for predicting response to molecularly
targeted agents has been limited to a very small list of mutated kinases. EGFR
activating mutations and the EML4-ALK genetic translocation, the two most
prominent examples that predict response to specific TKI’s, are, unfortunately,
fairly rare [12]. Thus, identifying clear targetable pathways has been possible for
only a small minority of patients. Complicating matters is the fact that obtaining
adequate tissue for molecular testing can be difficult [2, 13–15]. For these reasons,
a biomarker discovery effort that couples an innovative surgical approach with
kinase activity (‘‘kinomics’’) evaluation was sought for lung cancer patients.
Kinomic profiling refers to the determination of global kinase activity in a
specimen and is distinct from genomic and proteomic methods because it
determines changes in biological activity, not just the presence of a gene,
transcript, or protein [16]. Our lab utilizes the PamStation 12 (PamGene, B.V.,
Hertogenbosch, Netherlands), a fluorescent assay platform (Fig. 1) requiring very
small quantities of lysate that can measure the ability of active kinases in a
specimen to phosphorylate specific peptides, imprinted on multiplex arrays, in
real time with kinetic evaluation allowing for kinomic profiling of cells and tumor
tissue [17, 18].
As mentioned earlier, one of the limitations commonly faced in the clinic
relates to the difficulty in obtaining adequate tissue for molecular analysis
[2, 13, 19]. Fine needle aspirates of lung lesions may provide histologic diagnosis
and have shown some utility in specific molecular testing (ALK fusion and EGFR
mutation detection) [20, 21], but are often inadequate in quantity for more
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Fig. 1. Kinomic platform and Electromagnetic Navigation Bronchoscopy. (A) Overall experimental flow with a (B) Representative in-procedure display
of ENB and a schematic of PamChip assay used to measure basal kinomic activity displayed as (C) raw array picture of the 144 phosphorylatable peptides
and (D) phosphorylation changes with drug treatment displayed with illustration of comparative fluorescent detection below.
doi:10.1371/journal.pone.0116388.g001

extensive molecular profiling, including kinomics. Heretofore, to obtain larger
amounts of material required: a) that the lesion be resectable (i.e., early stage in a
medically fit patient); b) that the tumor be large; c) that the tumor be located in
proximal portions of the bronchial tree; and/or d) that the patient undergo more
invasive procedures. This is particularly evident in clinical trials for lung cancer
where obtaining fresh-frozen tissue (a requirement for kinomics and several other
microarray platforms) has been quite limiting.
Electromagnetic navigational bronchoscopy (ENB) can potentially overcome
some of these limitations by more reliably obtaining diagnostic material from
almost any location in the lungs in sufficient quantities to allow for molecular
testing [22]. ENB (Fig. 1) utilizes three key components to generate a ‘‘virtual’’
bronchoscopy: 1) a specially formatted computed tomography (CT) scan; 2) an
electromagnetic plate and chest wall sensors to monitor patient movement with
respiration; and 3) an extended working channel with a locatable guide. The
locatable guide allows the physician to navigate to the target lesion and biopsy
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specimens are taken under fluoroscopic visualization using forceps in a manner
that has been shown to increase clinical yield [22]. In the present study, we tested
the feasibility of using ENB-derived tissue specimens with kinomic profiling for
detecting biological activity in lung lesions.

Methods
Ethics
This study was conducted in accordance with the Declaration of Helsinki and was
approved by University of Alabama at Birmingham (UAB) Institutional Review
Board (IRB# X110411014). Written informed consent was obtained from all
patients.

Electromagnetic Navigational Bronchoscopy and Biopsy
Procedure
ENB utilizes a specially formatted CT scan to create a virtual bronchoscopy.
During the procedure the patient lies on an electromagnetic plate and chest wall
sensors monitor patient movement with respiration. A standard video bronchoscope is used with a 3 mm working channel. An extended working channel and a
locatable guide are passed through the bronchoscope’s working channel. The tip
of the locatable guide is sensed in the electromagnetic field. Registration points are
identified to match the virtual images to the patient’s anatomy. The locatable
guide is then navigated to the target lesion and biopsy specimens are taken under
fluoroscopic visualization. For this study, the tissue specimens were collected in
cryovials and immediately flash frozen in liquid nitrogen in the operating suite.
These specimens were transferred directly to the UAB Kinome Core (www.
kinomecore.com) and stored at 280 C until the kinomic assay was performed.
During the same ENB procedure, tumor specimen material was collected and
provided to UAB Pathology when clinically indicated. In some cases, the patient
already had a tissue diagnosis and underwent fiducial implantation for facilitation
of stereotactic body radiation therapy treatment planning and delivery. These
fiducials were placed after obtaining any biopsy material.

Sample Collection and Processing for Kinomic Profiling
Frozen tissue for each tumor was processed at 4 ˚C for kinomic profiling using
eppendorf tube pestle grinding followed by lysis in M-PER lysis buffer with
protease and phosphatase inhibitors per our standard protocol [23]. For those
patients without a prior cancer diagnosis, a simultaneously collected tissue
specimen was also sent to pathology for evaluation. Protein quantitation was
performed using standard BCA reaction assay. Based on total protein available for
each specimen, 5–10 mg of protein were combined with kinase buffer, ATP, and
fluorescently labeled anti-PY20 antibodies per UAB Kinome Core standard
operating procedure and then loaded into each well of the tyrosine (PTK)
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PamChips. The samples were run on the PamStation 12 kinomics workstation
(PamGene International, ‘s-Hertogenbosch, The Netherlands) using the standard
PTK PamChip protocol using Evolve12 Software (v. 1.5) as previously published
[23]. As lysates were pumped through the array, images were captured and
followed by analysis and quantitation performed using BioNavigator v. 5.1
(PamGene). Samples were excluded from subsequent ex vivo drug testing if they
had a) insufficient protein quantity, b) excessive temperature variation, c)
insufficient basal kinase activity. Western blotting to measure relative levels of
housekeeping proteins and total phospho-tyrosine was completed using 10%
SDS-PAGE gels, and transferred to Immobilon PVDF membranes (Merck,
Darmstadt, Germany) with 20 ug of sample loaded per lane, and detection with
1:4000 anti-phospho-tyrosine-HRP (Santa Cruz Biotechnology, Santa Cruz, CA,
scbt-508), 1:5000 mouse anti-GAPDH and rabbit anti-actin (Santa Cruz, scbt51907 and scbt-1616) with horseradish-peroxidase conjugated goat anti-mouse,
and donkey anti-rabbit antibodies (Jackson ImmunoResearch, West Grove, PA,
115-035-166 and 711-035-153).

Ex Vivo Drug Testing
Ex vivo kinomics testing was performed using the small molecule kinase
inhibitors, lapatinib, crizotinib, and erlotinib purchased from LC Laboratories
(Woburn, MA). Ex vivo testing [24] involved pre-mixing 25 mL aliquots of
protein extract (5 mg) from each tumor lysate prepared as above in separate tubes
with each drug at 20 nM, 0.5 mM, or 20 mM or vehicle (dimethylsulfoxide,
DMSO), incubating for 15 mins at 4 ˚C, adding kinase assay mix (Master Mix,
PamGene) and applying the mixture to an array of the PTK chip. Three chips (12
wells) were loaded with 35 mL of the mixture and inserted into the PamStation
where kinase activity and image capture took place over one hour. The PamChip
protocol and analysis using Evolve12 and BioNavigator were done as before with
the basal analysis.

Statistical Analysis
Primary analysis was performed using BioNavigator software v. 5.1 (PamGene).
Kinase activity data were produced to correspond to the phosphorylatablepeptide specific reaction per ‘spot’ on the PamChip. Raw signal intensity data per
each of the 144 spots was captured over multiple 50 ms exposures sequentially as
lysates were pumped through the array, and then over multiple exposure times
(10,20,50,100,200 ms) after lysates were rinsed off. These values were converted to
slopes of intensity by exposure time, and slopes were multiplied by 100 and log2
transformed for visualization and are labeled ‘‘log signal’’. Heatmaps of log signal
data were plotted in color corresponding with signal intensity (basal conditions)
or with log change from control (drug response). Unsupervised hierarchical
clustering of kinomic profiles for the samples was done using a Euclidean
distance, complete linkage R-script within BioNavigator. Variance filtering was
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also performed on the log signal transformed data with deviation from peptide
experimental mean per peptide in basal conditions. Dose-response heatmaps, are
displayed as the log ratio change from a DMSO control. Selected peptides were
plotted as raw kinetic values (‘‘prewash signal’’) over multiple 50 ms exposures to
demonstrate specific treatment-altered phosphorylation curves. A publically
available kinomic analysis tool containing the experimental data can be found at
http://kinome.github.io/public.

Results
Patient Characteristics
In this feasibility study, we consented and enrolled eight patients for kinomic
testing of ENB-derived material (Table 1), and all patients were seen and
evaluated for this study between October 14, 2011 and May 7, 2013. Eligibility
required that each patient show radiographic evidence for a lung mass lesion
(Shown in Fig. 2), and be scheduled to undergo an ENB procedure. The majority
of patients were women and the median age was 70.5 years of age (range, 49–82)
(Table 1). ENB-derived specimens were collected and flash frozen for kinomic
analysis within the operating room and were transferred at 280 ˚C to the UAB
Kinome Core within 5 minutes. Fig. 3 details the Consolidated Standard of
Reporting Trials (CONSORT) schematic showing the flow of the 8 patients who
were consented for the study. Of the 8 patients, 5 patients had ENB-biopsy
material sent to pathology while the remaining 3 patients had prior tissue
diagnosis of non-small cell lung cancer (NSCLC) and underwent the ENB
procedure solely for fiducial marker placement related to planned stereotactic
body radiation therapy (SBRT). As such, 3 patients did not have simultaneous
pathologic evaluation of the ENB-derived specimen. Pathological evaluation
yielded malignancy, normal lung, and necrosis in the numbers shown in Table 1.
Of note, one patient (#8) whose whole biopsy yielded normal lung parenchyma
was later shown on core biopsy to have squamous cell carcinoma. Kinomic
profiling was performed in a pathology-blinded fashion.

Tissue Quality
Protein quantification of the samples indicated that the tissue specimens were of
sufficient size to perform kinomic testing. Typical protein yield for an ENB biopsy
sample obtained by micro-forceps was ,378 mg/mL in approximately 150 mL of
total volume. Since kinomic testing requires between 1–5 mg of total protein
depending on array type (the serine-threonine kinome [STK] chip requiring 1 mg
and the tyrosine kinome [PTK] chip requiring 5 mg), the samples obtained were
more than adequate. Variation in loading control protein expression did not
always linearly correlate with measured total protein concentrations. Although
there was adequate protein, patients 2, 3, and 5 were not suitable for ex vivo drug
testing due to at least one of the exclusion criteria listed above. Pathologic
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Table 1. Patient characteristics and tumor evaluation.
Patient

Sex

Age

Pathology of Biopsy

1

F

77

NSCLC, MD-PD, favor adenocarcinoma

2

F

66

Necrosis, no viable neoplasm identified

3

M

49

Not obtained

4

M

73

Small cell carcinoma

5

F

73

Not obtained

Prior NSCLC diagnosis, fiducial placed for SBRT

6

F

68

Not obtained

Prior adenocarcinoma diagnosis, fiducial placed for SBRT

7

F

52

Alveolar tissue and cartilage fragments

Prior history of C/L lung adenocarcinoma

8

M

82

Lung parenchyma with no evidence of
malignancy

Core biopsy later showed squamous cell carcinoma

Median:

70.5

Range:

49–82

Comments

Prior NSCLC diagnosis, fiducial placed for SBRT

M-male; F-female; NSCLC-non small cell lung cancer; MD-PD-moderately differentiated to poorly differentiated; SBRT-stereotactic body radiotherapy.
doi:10.1371/journal.pone.0116388.t001

evaluation of patient 2’s specimen indicated that the area biopsied was necrotic
which would explain the relatively low level of kinase activity. Unfortunately, the
specimens obtained from patients 3 and 5 were not evaluated by pathology due to
prior diagnosis of non-small cell lung carcinoma (NSCLC). Of note, patient 3 had
previously received definitive chemoradiation to the region but had evidence of
progression by CT. Nevertheless, we cannot comment on the viability status of
those specimens.

Fig. 2. Patients’ computed tomography (CT) scans. CT scans show representative slices of the lung lesions (blue arrow) prior to ENB. Patient numbers
correspond to those listed in Table 1.
doi:10.1371/journal.pone.0116388.g002
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Fig. 3. CONSORT diagram on patient enrollment.
doi:10.1371/journal.pone.0116388.g003

Basal Kinomic Profiles
The basal kinomic profiles of all 8 patients are shown as unsupervised
hierarchically clustered heatmaps of log signal intensity for each phosphosubstrate
(Fig. 4; individual peptide phosphorylation curves can be visualized via http://
kinome.github.io/public). All 8 patients were analyzed as this was a feasibility
study, though only 2 of the 5 patients that had simultaneous pathology review had
viable cancer cells. There was a large variation in mean log signal intensity among
the samples consistent with the variety of tissues obtained (e.g., normal lung
parenchyma, necrosis, and carcinoma). We measured a maximum peptide log
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Fig. 4. Basal kinomic activity profiles. Unsupervised hierarchical clustering of basal (untreated) tyrosine kinomic profiles displaying log transformed slopeexposure for (A) all 144 peptides and (B) as change from sample mean and filtered for variance .1. Red in (A) indicates relative increased signal and in (B)
indicates an increase from sample mean. Blue indicates the opposite. Blue arrowhead points to red line denoting dendrogram separation. (C) Western
blotting of GAPDH and Actin is shown with sample concentration indicated for each patient.
doi:10.1371/journal.pone.0116388.g004

signal variance of 25.86, with mean peptide variance of 9.777. The standard
deviation from the experimental all-peptide mean (a surrogate for alterations of
global kinase activity on the chip) was 2.54 with the highest signal sample having a
mean log ratio change from the experimental mean of +4.13(PAT1) and the
lowest had a 22.02 (PAT7) log ratio change. Technical variance (aliquoted from
same master-sample, run on different arrays and chips) was measured across all
peptides (0 values excluded) at 2.7% CV. This was inline with previous
experiments where we had seen median technical and biological variance in
controlled cell lysates measured at 4.2% and 4.6% CV (data not shown).
Unsupervised hierarchical clustering identified 3 major clusters when the
dendrogram was cut at the level of the red line (blue arrow in Fig. 4A). Samples
are clustered by patient along the x-axis, and peptides along the y-axis. Two of
these clusters contained 4 NSCLC tumors (including one adenocarcinoma; PATs
-1, -3, -5, -6) and the other cluster contained no NSCLC (1 necrotic sample, 2
normal tissue samples, and 1 small cell carcinoma [SCC] sample). Fig. 4C displays
BCA calculated protein concentration per sample and actin and GAPDH
expression levels. Variance filtering for peptides with high variance (.10) was
used to further segregate and cluster in the heatmap in Fig. 4B, where peptides are
colored by deviation from experimental mean, clustering in similar groups as
before, and identifying very high relative log signal in variant peptides in PAT1
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and PAT6 as compared to the others. Thus, in general, confirmed malignancies on
pathological evaluation had higher signal intensity with samples from patient 1
and 6 being the highest (confirmed by anti-phosphotyrosine Western blot for
patients 1 and 6 is shown in S1 Fig.).

Ex vivo Kinase Inhibitor Testing
One of the major goals of this project was to determine whether or not ENBderived lung tumor specimens could be ‘‘biologically-interrogated’’ with small
molecule inhibitors. Because the kinomic platform used in this study directly
measures kinase activity, we could spike in small molecule kinase inhibitors to
determine the change in observed kinomic profiles for each specimen, potentially
providing drug response information prior to therapy. This ‘‘ex vivo’’ profiling of
lung tumor specimens collected by bronchoscopic means has not been reported to
our knowledge. Therefore, the samples demonstrating adequate signal intensity
were treated with either a vehicle control, or increasing doses of the small
molecule kinase inhibitors, crizotinib, erlotinib, or lapatinib at time of kinomic
evaluation. Hierarchical clustered heatmaps for log-transformed signal intensities
of the phosphosubstrates are shown in Fig. 5A. Interestingly, the drug response
data showed a more global attenuation of kinase signaling by crizotinib treatment,
but only for patients 1 and 6, tumors that also had the highest basal kinase activity
(mean log signal of all peptides). On the other hand, lapatinib treatment had a
very modest impact on kinase signaling. To further demonstrate the discrimination possible with ex vivo profiling, the entire kinetic profiles of the kinase assay
are shown for 3 of the phosphosubstrate probes for patients 1 and 6 (Fig. 5B).
Whereas the MBP_198_210 probe showed minimal increase in activity over the
course of the assay for both DMSO and drug treatment in patient 1’s specimen, in
patient 6’s tumor, this probe showed a time dependent increase in phosphorylation intensity for vehicle control (DMSO) treated specimens that was
attenuated by both erlotinib and crizotinib, but not by lapatinib. Alternatively, the
NPT2A_501_513 probe was phosphorylated in patient 1’s tumor and could be
attenuated by all three drugs while patient 6’s tumor showed no change in
phosphorylation under any condition. Finally, the PLCG1_764_776 probe showed
similar increase in phosphorylation for both patients, but only crizotinib could
attenuate this in both patients. Therefore, we feel that kinomic testing in this
manner can provide unique, therapeutic-specific information for lung cancer
patients.

Discussion
Adequate tumor tissue quantities for molecular analysis are a known problem in
the search for patient specific predictors of prognosis and treatment response
prediction [2], and the problem is most salient in patients whose lesions are not
accessible by conventional biopsy techniques. As can be seen in Fig. 2, the
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Fig. 5. Ex vivo drug response profile. Displays ex vivo drug response profiles as (A) a heatmap of kinase activity (log signal values) change from
untreated, clustered by row, of altered phosphopeptides per patient, per dose at 20 nM, 0.5 mM or 20 mM. (B) Ex vivo prewash kinetic peptide
phosphorylation (y axis per cell) over time (x axis per cell) of selected peptides in the selected samples, in response to indicated drugs at 20 mM. Blue lines
denote untreated, and green lines indicate treated phosphorylation curves.
doi:10.1371/journal.pone.0116388.g005
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peripheral location of some of these lesions would render them inaccessible to
conventional bronchoscopy; however, the ENB technique described above allowed
for the retrieval of adequate amounts of tissue for pathologic diagnosis and
kinomic analysis, and the fresh freezing technique did not eliminate the kinase
profile. It is possible that kinase signaling is changed to some extent through the
ENB collection, or through the liquid nitrogen flash freezing process, (essentially
stopping cellular kinase activity, proteolysis as well and other cellular processes).
However, it was impractical to collect and analyze fresh tissues without freezing
them to directly test this, as variation in time from collection to analysis could not
be controlled, and further, ourselves and others have successfully interrogated
kinase activity in flash frozen tissue from cellular, human, and animal tissues [25–
27].
Further refinement of this technique will involve optimizing patient selection
and improving the yield of acquiring tumor samples, as well as comparing a larger
cohort of samples against tissues acquired using a standard biopsy technique or
even better, from patients who ultimately undergo subsequent surgical resection.
In this way, we would be able to explore congruency between ENB-biopsy
material and primary resection specimen and will allow us to better determine the
impact of tumor heterogeneity on kinomic activity. One approach that is
currently being investigated is the use of confocal laser endomicroscopy (Cellvizio
system, Mauna Kea Technologies, Paris, France) during bronchoscopy procedures, including ENB. This ‘‘optical biopsy’’ can improve diagnostic yields since
neoplastic surface mucosa can be more readily distinguished from non-neoplastic
mucosa [28]. This may be especially useful in patients who will not be undergoing
surgical resection of lesions.
The basal heatmap (Fig. 4) intimates the possible utility of the combination of
ENB followed by kinomic analysis. First, tissue was obtained in adequate
quantities to produce this type of profiling data. Additionally, the patients appear
to show distinct differences in their basal profiles; of note, the unsupervised
analysis can be interpreted to have clustered NSCLC as opposed to all other tissue
types despite the small sample numbers (Fig. 4A). This clustering suggests that
kinomic analysis of ENB derived tissue will allow for patient and tumor specific
analyses as further knowledge of the lung cancer kinome and its relevance to
prognosis and treatment response is acquired. As an example, the type of kinomic
activity data shown in Figs. 4 and 5 have already been shown in rectal cancer to be
amenable to the creation of an accurate model to predict drug and radiation
treatment response [24], and a similar approach to lung cancer is likely feasible.
Furthermore, ex vivo small molecule inhibitor testing (Fig. 5A) appears to show
inhibition patterns that are both patient and drug specific. For example, note the
general inhibition seen as the mostly blue column at the highest dose of erlotinib
and crizotinib in patients 1 and 6 (Fig. 5A). Additionally, erlotinib appears to
show clustering of more specific peptide inhibition in patients 1, 7, and 8 but not
patients 4 and 6 (Fig. 5A). Patient 7 appears to show a specific inhibition pattern
seen at all concentrations and for all three of the inhibitors tested. The distinct
patient and drug-specific inhibition of kinase activity on single peptides is further
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visualized in Fig. 5B. For example, note how kinase activity on PLCG1_764_776
appears to be inhibited similarly by crizotinib in both patients 1 and 6; conversely,
erlotinib inhibition of the phosphorylation of this peptide seems stronger in
patient 1. S2 Fig. shows MetaCore generated network maps generated for these
data sets. While the importance of these particular findings remains unknown for
the patients included in this study, the findings demonstrate that this sort of
patient specific and drug specific kinomic response data is possible in the small
amount of tissue derived from ENB. Thus, the combination of ENB and kinomic
analysis will likely be useful in the discovery of relevant biomarkers for lung cancer
and in the creation of models and tests to predict tumor response to various small
molecule inhibitors.
Limitations of this study are primarily related to the small patient population
and incomplete pathological evaluation. For example, there are inadequate
numbers of known diseased tissue (and subtypes of diseased tissue) versus normal
tissue to allow for confident identification of relevant tumor markers.
Additionally, there are inadequate numbers of patients to build meaningful
models predictive of treatment response. Since some patients did not have a
specimen sent for pathological evaluation, we also cannot determine whether the
samples with low global kinomic activity was due to the presence of non-viable
tissue. As with standard biopsy collection methods, a limitation in molecular
analysis is that tumors are highly heterogeneous, even within a single solid tumor,
therefore making extrapolations from single biopsies to the entire tumor’s biology
is difficult. Comparative multi-site intra-tumor sampling analyses and comparison between ENB-derived tissues and standard biopsy derived tissues in the same
patient are generally not feasible from a clinical standpoint. Although this study
provides conceptual proof of the feasibility of prospective kinomic analysis of
ENB derived tissue, further research will be necessary to investigate the
application of this technique to the ‘‘precision medicine’’ landscape of lung
cancer.

Conclusion
This study demonstrates the feasibility of kinase activity microarray testing of
tissue derived by electromagnetic navigational bronchoscopy.

Supporting Information
S1 Fig. Anti-phosphotyrosine Western blot was performed for total protein lysates
from patient #1 and #6 (PAT1 and PAT6) using 1:3000 HRP-conjugated antiphosphotyrosine antibody with anti-actin as a loading control.
doi:10.1371/journal.pone.0116388.s001 (TIF)
S2 Fig. Top upstream kinases and network maps for each of the 3 differentially
phosphorylated substrates shown in Fig. 5. Peptides are listed (A–C) above tables
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of their respective Kinexus identified and ranked upstream ‘Kinases’ and Uniprot
ID’s. The percentage of times a kinase was present in a top-ten list upstream of a
phosphorylatable residue in the substrate is listed as ’%hits’. These upstream
kinases (red circles on network maps) identified were uploaded by Uniprot ID to
GeneGo MetaCore for network modeling (D–F, Djikstras shortest paths, with two
steps max between input kinases).
doi:10.1371/journal.pone.0116388.s002 (TIF)
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